Showing results (341-350 of 417) with videos related to
Sort By:
Pageof 42
Clinical Pharmacology and Therapeutics|January 1, 1977
Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassayN R Bachur, C E Riggs, M R Green, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062)A A Miller, G L Rosner, M J Ratain, et al.Biochemistry|October 22, 1996
Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivativesL Ratmeyer, M L Zapp, M R Green, et al.Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B studyS L Graziano, A Tatum, J E Herndon, et al.Medical and Pediatric Oncology|January 1, 1990
Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group BM R Green, A Kramar, R Schilsky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group BA A Miller, J E Herndon, D R Hollis, et al.Clinical Lung Cancer|January 1, 2004
Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancerH B Niell, M C Perry, G Clamon, et al.Seminars in Oncology|February 1, 1992
A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescueT C Shea, A M Storniolo, J R Mason, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2006
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerM R Green, G M Manikhas, S Orlov, et al.Seminars in Oncology|August 18, 2001
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignanciesC M Rocha Lima, J J Urbanic, A Lal, et al.Pageof 42